Premium
De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T‐cell lymphoma is associated with prolonged remission
Author(s) -
Wong Bryan Y.,
Ma Yupo,
Fitzwilson Robert,
Dang Nam H.
Publication year - 2008
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21177
Subject(s) - maintenance therapy , complete remission , medicine , peripheral t cell lymphoma , lymphoma , peripheral , oncology , gastroenterology , t cell , immunology , chemotherapy , immune system
Peripheral T‐cell lymphoma (PTCL) is an aggressive form of non‐Hodgkin's lymphoma (NHL), associated with poor prognosis and without standard approach to treatment. Denileukin diftitox (Ontak®) is a synthetic fusion protein combining the receptor‐binding domain of interleukin‐2 to the enzymatically active portion of diphtheria toxin. While approved for the treatment of cutaneous T‐cell lymphoma, it has demonstrated activity in non‐Hodgkin's lymphomas of both T‐cell and B‐cell origin. This report documents the first case of de novo maintenance therapy with denileukin diftitox sustaining an ongoing complete response at the molecular level for 2 years in a patient with PTCL. Am. J. Hematol. 2008. © 2008 Wiley‐Liss, Inc.